Uncategorized

BMS’ Krazati kneels to chemo in confirmatory colorectal cancer trial

Published

on

Patients treated with Bristol Myers Squibb’s Krazati in combination with cetuximab saw shorter median overall and progression-free survival than comparators on chemotherapy.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version